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Visual hallucinations are a feature of many psychiatric disorders,
including schizophrenia and bipolar disorder as well as proto-
typical conditions such as Charles Bonnet syndrome. However,
their prevalence is particularly high in Lewy body diseases
including Parkinson’s disease, Parkinson’s disease with dementia
and dementia with Lewy bodies; and in the latter up to 80% of
individuals are affected.1 Untreated, visual hallucinations in
dementia with Lewy bodies can markedly impair quality of life2
and significantly increase caregiver distress.3 However, although
a number of causative models for complex visual hallucinations
have been proposed (see, for example, Collerton et al,4 Diederich
et al,5 ffytche et al 6 and Manford & Andermann7) no specific
model has yet been proved definitive. Deafferentation models of
visual hallucinations, favoured in conditions such as Charles
Bonnet syndrome, suggest that defective sensory input from
the eye to the visual cortex can lead to the ‘release’ of visual
cortical areas and subsequent visual hallucinations.6,7 A similar
deafferentation process leading to hyperexcitability of the visual
cortex could also occur in dementia with Lewy bodies; certainly
across the Lewy body disease spectrum there is evidence for
pregeniculate dysfunction, including disturbances in retinal
dopaminergic circuitry, altered inter-retinal neural transmission
and neuropathological abnormalities in photoreceptors and outer
plexiform layers (for review, see Archibald et al 8).
Others have speculated that dysfunction in association areas
or impaired attentional binding is crucial to visual hallucination
formation in Lewy body disease.4,9 In dementia with Lewy bodies,
Lewy bodies in the inferior temporal cortex at autopsy have been
linked with visual hallucinations during life,10 there is extensive
parietal hypoperfusion11 and significant glucose hypometabolism
in visual association areas;12 these abnormalities combined with
posterior white matter disruption12,13 may lead to perturbations
in visual processing with disturbances in afferent inputs and
recurrent feedback loops. In support of this, a functional magnetic
resonance imaging (fMRI) study examining visual object
processing9 found that people with Parkinson’s disease with
visual hallucinations had reduced blood oxygen level-dependent
activation in lateral occipital and extrastriate temporal areas
compared with individuals with Parkinson’s disease who did not
hallucinate prior to image recognition. The authors argued that
this favoured the role of impaired bottom-up processing from
early visual areas to association areas in the pathogenesis of visual
hallucinations.
One way to provide further insights into the aetiology of
visual hallucinations in dementia with Lewy bodies is to
investigate whether cortical visual excitability, i.e. the responsive-
ness of visual cortex to external stimuli, is altered, and one
method of probing cortical excitability is through occipital
transcranial magnetic stimulation (TMS). This is a non-invasive
method of brain stimulation, which when applied over the
occipital cortex produces transient visual percepts called
phosphenes. The origin of phosphenes is likely to be within the
superficial dorsal occipital lobe since the current density generated
by TMS dissipates with the square of the distance. Thus
phosphenes have been presumed to arise from either direct
excitation of neurons within the visual cortex or from extra-
calcarine sites, although there is more consistent evidence that
phosphenes originate directly from excitation of the termination
of the optic radiation in Brodmann area 17 and excitation of
back-projecting fibres from Brodmann area 18/19.14 However,
regardless of stimulation site an intact striate visual cortex is
required for the perception of phosphenes15,16 and the phosphene
threshold, the stimulation intensity level at which phosphenes are
just perceived, is a reliable marker of the excitability of the visual
cortex.17,18
A number of studies have shown in dementia with Lewy
bodies that significant hypoperfusion and impaired glucose
metabolism occur in the occipital pole and these observations
would intuitively favour decreased early visual cortical
processing/excitability. Nevertheless, although these findings have
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Background
The aetiology of visual hallucinations is poorly understood in
dementia with Lewy bodies. Pathological alterations in visual
cortical excitability may be one contributory mechanism.
Aims
To determine visual cortical excitability in people with
dementia with Lewy bodies compared with aged-matched
controls and also the relationship between visual cortical
excitability and visual hallucinations in dementia with Lewy
bodies.
Method
Visual cortical excitability was determined by using
transcranial magnetic stimulation (TMS) applied to the
occiput to elicit phosphenes (transient subjective visual
responses) in 21 patients with dementia with Lewy bodies
and 19 age-matched controls.
Results
Phosphene parameters were similar between both groups.
However, in the patients with dementia with Lewy bodies,
TMS measures of visual cortical excitability correlated
strongly with the severity of visual hallucinations (P=0.005).
Six patients with dementia with Lewy bodies experienced
visual hallucination-like phosphenes (for example, seeing
people or figures on stimulation) compared with none of the
controls (P=0.02).
Conclusions
Increased visual cortical excitability in dementia with Lewy
bodies does not appear to explain visual hallucinations but it
may be a marker for their severity.
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been linked by some to the presence of visual hallucinations19,20
this has not been a consistent finding, with other studies
demonstrating that occipital perfusion can be normal in dementia
with Lewy bodies.21 In addition, O’Brien et al 22 found a
relationship between nicotinic receptor binding in primary and
secondary visual cortices and visual hallucinations in people with
dementia with Lewy bodies, but a lack of association with occipital
perfusion deficits, suggesting that significant functional receptor
changes can occur in the absence of obvious alterations in
perfusion. This, with the lack of observed neuropathology in the
occipital pole23 in dementia with Lewy bodies, would favour the
argument that the visual cortex is ‘structurally’ intact in
dementia with Lewy bodies and thus reduced visual excitability/
increased phosphene threshold is unlikely. The phosphene
threshold is decreased by factors such as light deprivation,24
pregeniculate blindness18 and migraine;25 these are all visual
cortical hyperexcitable states that are often associated with visual
hallucinations. Certainly reduced phosphene thresholds have
been observed in heavy users of ecstasy (3,4-methylenedioxy-
methamphetamine) who have visual hallucinations.26 Thus in
the present study we hypothesised that it would be likely that:
(a) phosphene thresholds would be lower rather than higher in
patients with dementia with Lewy bodies (patients with DLB) with
visual hallucinations compared with controls (healthy controls);
(b) in patients with DLB, lower phosphene thresholds would be
associated with more frequent and severe visual hallucinations.
Method
Participants
Twenty-one patients with DLB who had experienced visual
hallucinations at least once in the month before TMS testing were
recruited from a local community-dwelling population of patients
in the North-East of England. Nineteen age-matched controls
were selected from friends and spouses of patients included in this
and previous studies. The study was approved by the local ethics
committee. The patients with DLB underwent detailed physical,
neurological and neuropsychiatric examination. The diagnosis of
dementia with Lewy bodies was made independently by two
experienced senior clinicians using the revised International
Consensus Guidelines for dementia with Lewy bodies27 and all
study patients met criteria for probable dementia with Lewy
bodies.
All control and 18 of the 21 patients with DLB underwent
structural T1-weighted magnetic resonance imaging (MRI).
Cognitive function in all participants was assessed using the
Cambridge Cognitive Examination28 (CAMCOG, maximum
score 105) and the Mini-Mental State Examination29 (MMSE,
maximum score 30). The presence and severity of any extra-
pyramidal signs were graded using the motor component of the
Unified Parkinson’s Disease Rating Scale (UPDRS).30 The controls
demonstrated no evidence of dementia (from history and score
480 on CAMCOG). Exclusion criteria for all participants
included contraindications for MRI or TMS, severe visual impair-
ment, history of alcohol/substance misuse, use of benzodiazepine
or anticonvulsant medication, past neurological or psychiatric
history (apart from dementia), focal brain lesions on brain
imaging or the presence of other severe or unstable medical illness.
Patients with DLB were required to have a primary caregiver who
had regular daily contact with the patient.
All participants had measurement of their best near visual
acuity on Landolt broken rings or Snellen chart (test distance
40 cm) after correction of any refractive errors. Participants were
only included in the study if they had no visual field defects
and intact ocular movements on neurological examination.
Assessment of visuoperceptual function was carried out using
previously described angle discrimination and overlapping figures
tasks.31 Participants underwent 20 trials for each task and a
visuoperceptual score was derived (sum of scores) for further
analysis.
Prior to TMS testing in the patients with DLB, the primary
caregiver completed the Clinician Assessment of Fluctuation
(CAF) scale and the One Day Fluctuation Assessment Scale
(ODFAS).32 Clinically if patients demonstrated that they had a
new and sudden onset of marked cognitive fluctuations in the
24 h prior to TMS testing, which could be as a result of factors
such as an acute illness (for example, urinary tract infection) or
delirium, they were not tested until they returned to their prior
clinical state to avoid the potential confounding effects on
phosphene measures.
For assessment of visual hallucinations, the hallucinations
subscale of the Neuropsychiatric Inventory (NPIhall)33 was used
with specific reference to the occurrence of visual hallucinations
in the previous month, with the derived NPIhall score (frequency
6severity of hallucinations) subsequently used in analyses. For
reliability purposes, patients were asked independently from carers
about the occurrence of visual hallucinations in the month prior
to TMS using screening questions derived from the North East
Visual Hallucinations Inventory III;34 any discrepancies between
carer/family member and patient accounts of hallucinations were
discussed with both parties and the assessor, with reformulation of
NPIhall test scores (with primacy given to the opinion of the
caregiver).
TMS
Testing took place in a semi-darkened room and participants wore
an eye mask and were asked to keep their eyes closed during
stimulations (study duration approximately 1 h). To avoid the
potential influence of light adaptation on the phosphene
threshold,24 at 15min intervals, participants were exposed to
daylight-equivalent levels of luminance for at least 3min. The
TMS was applied using a handheld 70mm figure of eight coil
connected to two monophasic MagStim 2002 stimulators via an
intergated Bistim2 unit (MagStim Co, Dyfed, Wales). Paired pulse
occipital TMS across a range of interstimulus intervals (ISI, for
example between 2 and 50ms) has been demonstrated to facilitate
phosphene perception above single pulse stimulation (see for
example Kammer & Baumann,35 Sparing et al 36). In particular,
Sparing et al 36 observed with ISIs of between 3 and 12ms and a
conditioning stimulus set at 90% of the test stimulus, that normal
healthy participants perceive a higher number of phosphenes to
paired pulse compared with single pulse stimuli (factor increase of
1.6–1.8); in their study an ISI of 3ms appeared to be no different
from 12ms statistically although numerically an ISI of 3ms seemed
slightly more facilitatory. On this basis, in the present study, to
maximise phosphene response rate, we applied TMS using a
paired-pulse paradigm with the conditioning stimulus intensity
set at 90% of the test stimulus with an interstimulus interval of
3ms and with intervals at least 10 s between paired pulses.
The TMS coil was applied within a surface latex grid taped to
the occiput of the participant. The grid had 868 1-cm-spaced
points and was centred on the Oz point (10% of the nasion–inion
distance above the inion). The centre of the coil was placed on the
intersections of the grid, with the coil handle in the midline.
Current flow in the coil was craniocaudal. Nine grid intersection
sites were initially assessed for phosphenes in 2 cm steps from
2 cm to left of midline to 2 cm to the right and 2 cm above Oz
to 2 cm below. Mapping of stimulation sites was done in a
pseudo-random order to avoid serial order effects.
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Determination of phosphene threshold parameters
Participants initially had a period of time to become accustomed
to the stimuli and familiar with reporting phosphenes. At each
mapped grid site the phosphene threshold was determined by
increasing the stimulus intensity from 50% in a stepwise fashion
in 5% (relative to maximum stimulator output) increments up
to 100% of the stimulator output and decreasing the stimulus
intensity in 1% steps if phosphenes were elicited (stimulus
delivery maximum of 0.2Hz). Participants were asked to report
the location (ipsilateral, contralateral, central or bilateral), colour
and phenomenology of any visual or other subjective sensations
after each stimulus. Four stimuli were given at each stimulation
intensity and the lowest stimulus intensity required to elicit at
least one phosphene was defined as the phosphene threshold. This
lower threshold (P= 0.25 rather than P=0.50) was defined to
ensure that the number of participants who might not display
responses (i.e. had phosphene thresholds approaching or at
100% of stimulator output) was minimised.
As a control, sham stimulation was also given and randomly
interspersed with real stimulations (1:8 sham to real stimuli at a
stimulation intensity of between 100 and 120% of phosphene
threshold or 100% stimulator power if phosphene threshold was
not established). Sham stimulation involved tilting the coil away
from the head but with one winding remaining in contact with
the scalp.
In a subset of participants (10 controls and 9 patients with
DLB) in whom phosphenes could be reliably reproduced and
who were willing to tolerate extended study, a stimulation–
response protocol at the map site with the lowest phosphene
threshold (see point (a) below) was applied. Eleven stimulation
intensity levels were defined around this threshold (five above
and five below in 2% increments of maximum stimulator output)
for each participant and ten stimuli were given at each level
(random order) and the frequency of phosphene elicitation at
each stimulation intensity level was recorded.
Data analysis
Two TMS outcome measures were analysed to assess visual cortex
excitability.
(a) Phosphene threshold: the threshold at the optimal stimulation
site for participants who demonstrated phosphenes. It is
established that given the stimulation intensity limits of
TMS, not all individuals will experience phosphenes even at
the maximum stimulation output (see for example Kammer
et al,14 Cowey & Walsh,15 Silvanto et al,16 Kammer et al,17
Boroojerdi et al,24 Gerwig et al,25 Kammer & Baumann,35
Sparing et al36). Therefore to ensure inclusion of all
participants in analyses, participants who did not display
phosphenes up to 100% stimulator output (i.e. had thresholds
above 100%) were arbitrated a phosphene threshold of 101%.
(b) Phosphene response rate: this is the number of mapped sites
(with each site stimulated up to 100% of the stimulator
output) at which phosphenes can be elicited (out of a
maximum of nine).
Brain atrophy occurs in dementia with Lewy bodies, although
whether it affects the occipital lobe is controversial.37 Nevertheless
we used structural magnetic resonance scan data to control for
possible differences in occipital atrophy between the patient and
control groups since for every millimetre the surface cortex is away
from the stimulating coil, approximately an additional 3% of the
maximum power output is required to induce an equivalent level
of brain stimulation at the motor cortex.38 Left and right occipital
poles were defined in standard Montreal Neurologic Institute
(MNI) space and these points were transformed into each
participant’s raw image space using SPM 8 for Windows
(Statistical Parametric Mapping, London). The nearest scalp
points (left and right) were defined; a line between each of the
brain points and their corresponding scalp points provided the
long axis for 1 cm diameter cylinders. Non-brain volume was
calculated and divided by the cross-sectional area of the respective
cylinders, to provide averaged (left and right) scalp-to-occipital-
surface distances (scalp–occipitald). Repeat analyses were then
performed using an adjusted phosphene threshold ratio
(phosphene threshold/scalp–occipitald) to account for possible
group differences in atrophy.
Primary correlation analyses assessed the relationship between
NPIhall in patients and phosphene parameters. Secondary analyses
examined the association between key demographic/disease
factors (age, visual acuity, UPDRS motor subscale score,
CAMCOG score, visuoperceptual score and CAF score) and
phosphene parameters in controls and patients where appropriate.
Parametric and non-parametric statistics were applied
according to normality of the data using SPSS 17 for Windows.
All values reported are means and standard deviations unless
otherwise stated.
Results
Demographic characteristics
The patients with DLB and the controls were similar in terms of
age, gender and visual acuity (Table 1). As expected, UPDRS
motor scores were significantly higher and cognitive test and
visuoperceptual task scores significantly lower in the patients
compared with the controls. The distribution of NPIhall scores
for patients was positively skewed (median 3, range 1–8) with a
significant proportion (7 patients) having a NPIhall score of 1;
NPIhall data were consequently analysed non-parametrically.
Phosphene characteristics
All participants tolerated the study and TMS reliably elicited
phosphenes in a similar proportion of controls and patients (17/
19 (90% of controls), 17/21 (82% of patients); Fisher exact test,
P= 0.66). Sham stimulation produced phosphenes in only two
participants (one control on one of the sham stimulations, one
patient on six different sham stimulations). Of note, when the coil
was held more anteriorly (over motor cortex) and fired, neither of
these participants reported any phosphenes.
Phosphenes occurred predominately in either the lower
contra-lateral hemifield or near the fovea. The subjective
characteristics of the phosphenes experienced are shown in
Table 2. Six patients but no controls experienced seeing transient
complex figures and objects after TMS (Fisher exact test, P= 0.02)
with some overlap between the phenomenology of these and the
individual’s visual hallucination history (Appendix). In patients
who experienced these visual hallucination-like phosphenes
(Appendix), they occurred infrequently (55% of stimuli
administered) between the more common classic phosphenes
and were unrelated to stimulation intensity. In addition these
patients had higher NPIhall scores (median 5.0 (IQR= 3.0)
compared with those who did not (median 2.0 (IQR= 3.0);
Mann–Whitney U-test 17.5, P= 0.03) and worse visuoperceptual
scores (median 22.5 (IQR= 17.3) v. median 34.0 (IQR= 8.0);
U=20.0, P=0.05). There was also a trend for these patients with
DLB to have lower phosphene threshold scores (median 65.0
(IQR= 29.8)) compared with those who did not experience visual
hallucination-like phosphenes (median 80.0 (IQR= 41.0)) and
also higher phosphene response rate (median 8.0 (IQR= 3.0) v.
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median 4.0 (IQR= 8)) although this did not reach significance
(phosphene threshold: U=23.5, P=0.10; phosphene response
rate, U=23.0, P= 0.09).
Comparison of phosphene parameters across groups
As expected there was a negative correlation between phosphene
threshold and phosphene response rate (i.e. lower threshold, more
sites demonstrating phosphenes) in both controls and patients
(controls: Kendall’s t=70.67, P50.001; patients: t=70.69,
P50.001). There were no significant differences between the
controls and patients for phosphene threshold (controls: median
65% (IQR= 44%); patients: median 72% (IQR= 41%);
U= 177.5, P= 0.56) and phosphene response rate (controls:
median 4.0 (IQR= 8.0); patients: median 6.0 (IQR= 7.5);
U= 178.5, P=0.57, Fig. 1). Stimulus response plots were
comparable for controls and patients (Fig. 2); phosphene
thresholds were similar between controls and patients included
in the stimulation response paradigm (controls: 55.6%
(s.d. = 8.8%); patients: 59.4% (s.d. = 12.1%); t=0.69, P=0.50)
and there were no significant differences in phosphene frequency
between the controls and patients across the 11 stimulation
intensities used (mean difference patients minus controls: 1.0%
(s.d. = 7.6 %), F=0.21, P=0.65).
Despite no differences between the controls and patients with
regard to phosphene parameters and stimulus response plots, in
the patients there was a negative correlation between NPIhall score
and phosphene threshold (t=70.49, P=0.005, Fig. 3(a)) and a
positive association with phosphene response rate (t= 0.61,
P= 0.001, Fig. 3(b)).
Given the relationship between NPIhall score and phosphene
excitability, we retrospectively analysed whether or not the relative
complexity of phosphenes experienced by both controls and
patients was associated with the phosphene parameters; a
phosphene complexity score was defined with one point given
for each subjective feature of the phosphenes elicited in a given
participant: simple phosphene, two-dimensional geometric shape,
single colour (other than white/grey), polychromatic, moving
phosphene, and any complex visual hallucination-like phosphene,
for example figures/objects. Thus scores could potentially range
from zero to six. Phosphene complexity scores were similar for
both controls and patients (controls: median 1.0 (IQR= 2.0);
patients: median 1.0 (IQR= 3.0); U= 178, P=0.56) and they
showed a negative correlation with phosphene threshold (controls:
t=70.54, P= 0.003; patients: t=70.67, P50.001, Fig. 3(c)) and
a positive correlation with phosphene response rate (controls:
t= 0.49, P= 0.009; patients: t= 0.55, P= 0.002, Fig. 3(d)). In
patients, the phosphene complexity score also correlated positively
with NPIhall score (t= 0.49, P= 0.006).
Association of phosphene parameters and NPIhall
scores with key demographic/disease factors and
medication
In both controls and patients, increasing age was negatively
associated with phosphene response rate (controls: t=70.40,
P= 0.02; patients: t=70.36, P= 0.04) although not with
phosphene threshold but there was no association between the
phosphene parameters and visual acuity. In the patients there
was no association between phosphene parameters and
CAMCOG, UPDRS or visuoperceptual scores although there
was a positive correlation between CAF scores and phosphene
response rate (t=0.37, P=0.03).
The NPIhall scores were positively associated with CAF scores
(t=0.42, P= 0.02) although not with other demographic/disease
factors (age, visual acuity, UPDRS motor subscale score,
CAMCOG score and visuoperceptual score). There were no
significant differences in phosphene threshold or phosphene
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Table 1 Demographic, cognitive and motor characteristics of participants included in studya
Controls (n=19) Patients (n=21) P
Age, years: mean (s.d.) 77.6 (7.1) 80.6 (5.9) 0.15
Gender, males:females 11:8 12:9 0.96
Unified Parkinson’s Disease Rating Scale motor subscale, mean (s.d.) 0.9 (1.6) 34.3 (15.2) 50.001
Mini-Mental State Examination, mean (s.d.) 29.0 (1.2) 19.1 (5.4) 50.001
Cambridge Cognitive Examination, mean (s.d.)
Total score 96.5 (3.4) 65.8 (15.1) 50.001
Executive subscore 22.1 (3.4) 10.6 (5.1) 50.001
Memory subscore 23.6 (2.1) 15.5 (4.2) 50.001
Visual acuity, decimalised 0.64 (0.29) 0.56 (0.25) 0.36
Visuoperceptual score, % correct: mean (s.d.) 39.8 (0.4) 30.1 (8.2) 50.001
Clinician Assessment of Fluctuation, mean (s.d.) – 8.4 (4.2) N/A
One Day Fluctuation Assessment Scale, mean (s.d.) – 5.6 (4.6) N/A
On cholinesterase inhibitors, yes:no – 16:5 N/A
On anti-Parkinsonian medication, yes:no – 6:15 N/A
L-dopa dose equivalent, mg:b mean (s.d.) – 262.5 (173.4) N/A
a. For comparison of data in controls v. patients, independent Student t-tests were used for continuous data and Pearson chi-squared for categorical data. Results in bold are
statistically significant.
b. Calculated equivalent L-dopa dose in those patients on dopaminergic medication.
Table 2 Characteristics of elicited phosphenesa
Controls,
n (%)
Patients,
n (%) P
Participants in whom
phosphenes were elicited 17/19 (89.5) 17/21 (80.9) 0.67
Phosphene characteristics
Simple 17/17 (100.0) 17/17 (100.0) 1.00
2D geometric shape 4/17 (23.5) 7/17 (41.2) 0.46
Coloured 7/17 (41.2) 9/17 (52.9) 0.49
Polychromatic 3/17 (17.6) 7/17 (41.2) 0.26
Moving 1/17 (5.9) 0/17 (0.0) 1.00
Visual hallucination-like 0/17 (0.0) 6/17 (35.3) 0.02
a. Comparison of groups on basis of chi-squared or Fisher exact tests where
appropriate. Results in bold are statistically significant.
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response rate in patients on or off cholinesterase inhibitors or
anti-Parkinsonian drugs. Correlational analyses of phosphene
parameters against NPIhall score restricted to patients taking
cholinesterase inhibitors (phosphene threshold: t=70.63,
P= 0.002; phosphene response rate: t= 0.67, P=0.001) were
consistent with the overall group relationships.
Use of anti-Parkinsonian medications did not significantly
alter NPIhall scores although patients on cholinesterase inhibitors
appeared to have higher NPIhall scores (on cholinesterase inhibitors,
median 4.0 (IQR =4.5); not on cholinesterase inhibitors, median
1.0 (IQR= 1.0), U= 14.0, P= 0.03). This may have been because
the cholinesterase inhibitors were being used to treat visual
hallucinations in dementia with Lewy bodies, as is currently
recommended practice. A prior history of rapid eye movement
(REM) sleep behaviour disorder in patients (11/19) was not
associated with increased NPIhall score nor any difference in
phosphene parameters. It is important to note that these were
exploratory analyses uncorrected for multiple comparisons and
thus significant findings should be treated with caution.
Influence of scalp–occipital distance
on phosphene threshold
Scalp–occipitald were similar for controls (13.5mm (s.d. = 2.0))
and patients (14.3mm (s.d. = 2.3); t= 1.16, P= 0.25). There were
no significant differences between controls and patients (controls:
median 5.41%/mm (IQR=2.87); patients: median 5.39%/mm
(IQR= 3.08); U= 145.0, P=0.62) using an adjusted phosphene
threshold to account for scalp distance (phosphene threshold/
scalp–occipitald).
Discussion
This is the first study that we are aware of that uses TMS to
investigate cortical visual excitability in dementia with Lewy
bodies. Phosphenes were elicited reliably in the majority of
controls and patients with DLB and this is likely to be related to
the paired pulse paradigm36 and threshold methodology applied.
Age-related effects (most studies are in young healthy adults) on
phosphene perception are not known, although analogous analysis
of motor cortical excitability has suggested an increase in
thresholds with age.39 Part of this effect is presumed to be
mediated by increasing scalp-to-brain-surface distances. In the
present study there was no relationship between phosphene
threshold and the scalp-to-occipital-cortex distance in either
controls or patients, suggesting that this was unlikely to have been
a factor contributing to the phosphene threshold values observed.
Phosphene characteristics
In age-matched controls, the visual characteristics of the induced
phosphenes were comparable with those described in previous
studies.14–17,24,25,35,36 In addition we found that: (a) phosphenes
could be elicited from the majority of patients with DLB; (b)
phosphene thresholds and phosphene response rates were not
significantly different between groups; and (c) the input–output
characteristics on stimulation response plots were comparable in
the controls and patients tested. The results suggest that, first,
the process of phosphene induction in controls and patients with
DLB is similar and, second the structural neuronal integrity of the
visual cortex activated by TMS is likely to be intact in people with
dementia with Lewy bodies, which is consistent with the relative
paucity of neuropathology in the occipital lobe.23
However, our findings do not support our first hypothesis that
we would see increased visual cortical excitability in our patients
compared with controls. Nevertheless, we found evidence to
support our second hypothesis that there would be a positive
correlation between the degree of visual cortical excitability as
evidenced using TMS and the severity and frequency of visual
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Fig. 1 Boxplots showing phosphene parameters in all
participants (minimum, first quartile, median, third quartile and
maximum displayed).
(a) Phosphene threshold boxplot – there were no significant differences between the
controls and patients for phosphene threshold (P= 0.56). (b) Phosphene response rate
boxplot – there were no significant differences between controls and patients for
phosphene response rate (P = 0.57).
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Fig. 2 Stimulus response plot averaged across subgroups of
controls (n = 10) and patients with dementia with Lewy bodies
(n =9) who underwent the stimulus response paradigm.
The Y-axis shows response rate expressed as a percentage of responses (out of 10)
at a given stimulation intensity. The x-axis shows stimulation intensity expressed as
a % of stimulator output relative to phosphene threshold.
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hallucinations experienced. How might we reconcile the lack of
difference between the groups in terms of visual cortical
excitability yet explain this association between the phosphene
parameters and visual hallucinations in the patients with DLB?
One explanation may be that the patients with DLB are
bimodal with regard to their visual cortical excitability. Certainly
in some patients with DLB the visual cortex could be more
disconnected from excitatory drive (either top-down or bottom-
up) as a result of pathological changes (for example, within the
white matter). In others, compensatory mechanisms mediated
by, for example, cholinergic receptor upregulation22 or loss of
feedback/feedforward inhibition, may predominant, producing a
contrary hyperexcitability state that predisposes such individuals
to visual hallucinations. However, we did not see any clear
dichotomy in the distribution of phosphene thresholds of the
patients; indeed the spreads of distribution for the phosphene
parameters were remarkably similar between controls and patients
(Fig. 4).
An alternative explanation is that the phosphene parameters
are inherent to the individual’s ‘premorbid’ neurobiology and that
differing levels of intrinsic visual cortical excitability contribute to
the predilection in some individuals towards visual hallucinations
when they develop pathological changes in the visual system.
Certainly there is evidence in healthy individuals of significant
differences in visual processing activity in relation to phosphene
response/non-response to occipital TMS.40 However, this is a
highly speculative argument that cannot be adequately tested
within the present study and longitudinal studies examining the
evolution and worsening of visual hallucinations in individuals
with visual hallucination-prone diseases and any changes (or lack
of) in phosphene parameters would be needed. In addition, a
causal relationship between visual cortical excitability and visual
hallucination severity and whether increased excitability leads to
increased visual hallucinations or vice versa cannot be determined
from the present data; it is possible that there is an inverse
relationship between phosphene threshold and NPIhall score
497
8 –
7 –
6 –
5 –
4 –
3 –
2 –
1 –
0 –
0 20 40 60 80 100
Phosphene threshold (%)
N
P
Ih
a
ll
5 –
4 –
3 –
2 –
1 –
0 –
0 20 40 60 80 100
Phosphene threshold (%)
8 –
7 –
6 –
5 –
4 –
3 –
2 –
1 –
0 –
N
P
Ih
a
ll
5 –
4 –
3 –
2 –
1 –
0 –
P
h
o
sp
h
e
n
e
co
m
p
le
xi
ty
P
h
o
sp
h
e
n
e
co
m
p
le
xi
ty
0 1 2 3 4 5 6 7 8 9
Phosphene response rate
0 1 2 3 4 5 6 7 8 9
Phosphene response rate
;
; ; ; ;;
; ; ;
; ; ;
; ;
;
;; ; ;
;
; ;;
; ; ;
;
;
; ;
;
;
;;
- - - <
-
- < - --
< < < --
< - < < <
<--<-< <- < <-
<-
Controls
Patients
Controls
Patients
<
-
- < -
< < <
< < < <
< <- - -< < - < <-
< - -
(a) (c)
(b) (d)
Fig. 3 Scatter plots showing phosphene parameters in patients with dementia with Lewy bodies (DLB) against Neuropsychiatric
Inventory (NPIhall) score ((a) and (b)). (c) and (d) show phosphene parameters in all participants against phosphene complexity scores.
(a) NPIhall v. phosphene threshold: significant negative correlation (t=70.49, P=0.005); (b) NPIhall v. phosphene response rate: significant positive correlation (t=0.61, P=0.001).
(c) Complexity score v. phosphene threshold: controls and patients showed a negative correlation with phosphene threshold (controls: t=70.54, P=0.003; patients: t=70.67,
P50.001); (d) complexity score v. phosphene response rate: controls and patients showed positive correlation with phosphene response rate (controls: t=0.49, P=0.009;
patients: t =0.55, P=0.002). Vertical line in (a) demarcates maximum stimulation intensity; four patients had thresholds 4100%. Lines in (c) and (d) show linear fits to data
(dark blue: controls; light blue: patients).
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because visual cortical excitability is a state-related measure or
marker for more severe visual hallucinations in people with
dementia with Lewy bodies.
Two other significant findings were, first, the observation that
a significant minority of patients with DLB who had more marked
visual hallucinations experienced visual hallucination-like
phosphenes such as people or objects, and second, that there
was a clear association between the complexity of phosphenes
experienced and increased excitability to TMS in both controls
and patients.
The origin of phosphene induction and its conscious
perception although interrelated are unlikely to be co-localised,
with the latter dependent upon the integrity of higher-order
networks and extensive recurrent processing.41 The complexity
of phosphenes elicited supports this by suggesting that localised
occipital TMS leads to activation of higher visual areas. Thus it
is likely that individuals with inherently increased excitability to
occipital TMS have either a progressive increase in the
propagation of TMS-evoked activity from early visual areas to
higher areas or enhanced phosphene perception within higher
visual areas themselves.
There was a trend for the patients in our study to have a
greater phosphene complexity for a given phosphene threshold/
phosphene response rate compared with the controls (Fig. 3(c)
and (d)) and this may suggest that there is a baseline shift in
the responsiveness of higher visual processing areas to inputs from
earlier visual areas either as a result of pathological hyperexcitability
in these areas or a loss of inhibition. Thus in those patients with
an inherently more active/excitable early visual cortex, TMS may
occasionally elicit visual hallucination-like phosphenes and
predispose them overall to visual hallucinations. The inverse
association between phosphene threshold and NPIhall score and
the observation of possible lower phosphene threshold in people
who experienced visual hallucination-like phosphenes would
support this. In addition the phenomenology of the visual
hallucination-like phosphenes (people and objects) experienced
could indicate abnormal ventral stream/temporal lobe activation,
which has been proposed as a mechanism for the production of
visual hallucinations.6
However, both imaging and post-mortem studies have
demonstrated that there are pathological occipital white matter
changes and disruption to visual association areas in dementia
with Lewy bodies.12,13 Therefore, alternatively, the visual
hallucination-like phenomena may be arising as an intrinsic
misinterpretation of the induced phosphenes at higher visual
processing levels as a result of impaired bottom-up transmission.
As discussed previously, there is evidence for impairment in
bottom-up processing in people with Parkinson’s disease with
visual hallucinations9 and the contribution of bottom-up
processing impairment in visual hallucination manifestation
would be consistent with the observation that patients with
DLB frequently have illusionary experiences and marked visuo-
perceptual errors to normal external visual stimuli.28 Furthermore
the role of impaired bottom-up processing is supported, in our
study, by the higher frequency of occurrence of visual
hallucination-like phosphenes in the patients with DLB with poor
visuoperceptual task performance.
It has also been hypothesed that brainstem and subcortical
lesions that affect ascending cholinergic, dopaminergic and
serotonergic projections and their interaction with thalamo-
cortical, basal ganglia and corticocortical neural circuitry may lead
to visual hallucinations.7 In dementia with Lewy bodies, in
particular, there are changes in cholinergic function within
thalamic and visual associative areas that may cause visual
hallucinations; certainly the clinical observation that cholinesterase
inhibitors ameliorate visual hallucinations42 would support this.
Cholinesterase inhibitor use could thus be a confounder in our
data; intuitively one might expect individuals on cholinesterase
inhibitors to have less marked visual hallucinations and lower
visual cortical excitability on TMS. However: (a) subgroup
analysis of patients on cholinesterase inhibitors showed that the
relationship between NPIhall score and phosphene parameters
was maintained, suggesting that treatment by these agents was
not an influencing factor; (b) we found no difference in our study
between patients on or off cholinesterase inhibitors with regard to
the visual cortical excitability; and (c) patients not on
cholinesterase inhibitors appeared to have lower NPIhall scores
(although this was not significant after correction for multiple
testing). This last observation is contrary to what one might
expect if these agents have a treatment benefit for visual
hallucinations.
Visual hallucinations have also been postulated to be
associated with sleep disturbance and dream overflow.5 The
occurrence of REM sleep behaviour disorder in dementia with
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Fig. 4 Histograms showing frequency distribution of (a) phosphene threshold and (b) phosphene response rate in controls and patients.
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Lewy bodies is particularly frequent as a result of brainstem
pathology, and in Parkinson’s disease there is some evidence of
an association between REM sleep behaviour disorder and the
occurrence of visual hallucinations.43 However, in the present
study we found no relationship between the presence/absence of
REM sleep behaviour disorder and hallucination severity or,
indeed, phosphene threshold or phosphene response rate.
Overall, the aetiology of visual hallucinations in dementia with
Lewy bodies is likely to be distributed across multiple neural
substrates8 although mechanistically we would argue that visual
cortical excitability either as a process, or a state-related measure,
is central in the manifestation of visual hallucinations in dementia
with Lewy bodies.
Strengths and limitations
Strengths of this study were the inclusion of individuals diagnosed
according to formal diagnostic criteria and verification by
consensus. In addition participants underwent detailed neuro-
psychological testing and a rigorous protocol for assessment of
TMS-induced phosphenes. A limitation of the present study is
the lack of a comparator disease group and/or a group with
non-hallucinating dementia with Lewy bodies; thus it is not clear
whether our findings of association between visual hallucinations
and phosphene parameters are driven by the presence/absence of
visual hallucinations, Lewy body-related neuropathophysiology
or a general neuropathophysiological alteration associated with
dementia per se.
In addition, although we found no evidence for an effect of
cholinesterase inhibitors on the phosphene parameters, given
the small number of patients not on cholinesterase inhibitors
(n= 5) our study may not have been sufficiently powered to detect
such a difference and thus the potential confounder effect of these
medications needs further investigation.
Finally, the detection of phosphenes relied upon the subjective
perception of the participant, which may be compromised by
cognitive impairment, although we found no evidence for excess
reporting of phosphenes in our patients, as evidenced by a lack
of response to sham stimuli. Conversely, it could be argued that
there may be a significant number of false-negative reports as a
result of perceptual and attentional disturbances in patients with
DLB and thus the true phosphene threshold is actually a lot lower
in this group. Several factors, however, mitigate against this. First,
the dispersion of phosphene threshold values across patients was
no different from controls (Fig. 4(a)). Second, there was no
correlation between decreased phosphene excitability and
increased severity of cognitive fluctuations or lower cognitive
scores, which one might expect if there were an association
between decreased cognitive function and increased false-negative
reporting.
Implications
The similarity in the phosphene parameters and their phenomen-
ology between controls and patients with DLB suggest that the
visual cortex in itself is not overtly abnormal in dementia with
Lewy bodies. The positive association between excitability and
visual hallucination severity suggests that the latter may be a
marker for visual hallucinations, although any causal link between
the two cannot be determined from the present study.
An alternative possibility to explain our findings is that the
frequency and severity at which visual hallucinations are
experienced may depend upon an individual’s premorbid visual
cortical excitability combined with subsequent pathological/
plastic changes either within the visual system or in neural systems
external to the visual system but with a significant influence on it
(for example, ascending cholinergic projections). Further studies
in people with non-hallucinating dementia with Lewy bodies
and other dementias such as Alzheimer’s are required to
determine the specificity of the findings in the present paper.
In addition, studies characterising how phosphene parameters
relate to the known posterior perfusion deficits in dementia with
Lewy bodies and cortical visual function in early visual areas and
association areas as measured by, for example, fMRI may help
further elucidate the pathophysiology of visual hallucinations
and visuoperceptual deficits evident in dementia with Lewy
bodies. The contribution of the cholinergic system could also be
examined using TMS in patients before and after cholinesterase
inhibitor initiation. In addition, the use of occipital TMS,
particularly if optimised to elicit visual hallucination-like
phosphenes, may provide a powerful endophenotypic approach
to investigating visual hallucinations in dementia with Lewy
bodies and other visual hallucination-prone diseases.
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Appendix
Subjective report of visual hallucination-like
phosphenes in patients with dementia
with Lewy bodies
Patient Comment during transcranial
magnetic stimulation
Predominant phenomenology
of prior visual hallucinations
No. 2 ‘I saw a young man’, ‘There
was a man with a round
body’.
Seen disembodied faces as well
as figures ‘all in black’ and
animals. Frequently reported
seeing writing on walls and
on furniture.
No. 5 ‘A shadowy figure of
someone’.
Seen children and ‘shadow
people’. Also reported seeing
giant flowers in the garden and
people in photographs ‘moving’.
No. 10 ‘Lots of people and children
appeared’.
Seen children and people.
No. 11 ‘There was a person. I couldn’t
make out their features’.
Seen insects and small ‘black
lumps’.
No. 12 ‘There was a football player
in a red top who then
disappeared’.
Seen children playing and
animals under tables.
No. 19 ‘There was a table, maybe a
plank of white wood’.
Seen cats lying in bed. Also
recurrently seen dead mother.
Taylor et al
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